China Needs Stricter Requirements on Cheaper Biologic Drugs

China needs more stringent rules for approval of less expensive versions of biologics, complex drugs made from living cells, to ensure their safety and effectiveness, according to an industry report.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.